Alpha Tau FY26 H1 net loss more than doubled to $68.8 million
DRTS•FY26 first-half results
Alpha Tau reported a net loss of USD 68.8 million, or USD 0.76 per share, for the six months ended June 30, 2026.
Research and development expense climbed to USD 20.9 million from USD 14.2 million a year earlier on higher compensation, trial activity, and raw materials.
Financial expense swung to USD 41.4 million from financial income of USD 315,000, driven by warrant liability remeasurement.
Cash position and Tolmar update
Cash, cash equivalents, short-term deposits, and restricted deposits rose to USD 104.8 million at June 30, 2026, from USD 76.9 million at Dec. 31.
The Tolmar deal included a USD 20 million equity investment, USD 15 million for U.S. manufacturing, and up to USD 161.5 million in milestones. ReSTART enrolled 88 patients.
